Neuromedical's injunction against NeoPath blocked:
This article was originally published in Clinica
NeoPath has won its first courtroom battle concerning a threatened injunction by Neuromedical Systems. The April 1997 action from Neuromedical alleged patent infringement and demanded that NeoPath cease manufacture, sales and expansion of use of its AutoPap 300 QC System. It was thrown out by The US District Court last month. The Redmond, Washington-based NeoPath says that it will vigorously defend the action.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.